P1.23-08 Clinical Utility of Combined Plasma and Tissue NGS in Patients with Advanced, Treatment-Naïve, Non-small Cell Lung Cancer
2023; Elsevier BV; Volume: 18; Issue: 11 Linguagem: Inglês
10.1016/j.jtho.2023.09.436
ISSN1556-1380
AutoresH. Bote de Cabo, Marco Siringo, Esther García-Lorenzo, Adauto Castelo, Esther Conde, Susana Hernández, Fernando Lopez-Rios Moreno, M. Herrera, Javier Baena, Yolanda Ruano-Domínguez, Ana B. Enguita, Uri Harold Pérez Guerra, Luis Paz‐Ares, Jon Zugazagoitia,
Tópico(s)Lung Cancer Research Studies
ResumoThe incremental clinical value of performing both tissue and plasma next-generation sequencing (NGS) to detect actionable alterations (AA) in advanced non-small cell lung cancer (aNSCLC) has not been comprehensively assessed. We aimed to study the clinical utility of performing both techniques in patients with newly diagnosed aNSCLC.
Referência(s)